SharesGrow.com Intrinsic Value of S&P & Nasdaq Contact Us

हिन्दी

← Back to all stocks

ETHZilla Corporation Common Stock ATNF NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • US • USD

SharesGrow Score

SharesGrow Intrinsic Value

Negative cash flow

ETHZilla Corporation Common Stock (ATNF) is a Biotechnology company in the Healthcare sector, currently trading at $7.04. It has a SharesGrow Score of 14/100, indicating a weak investment profile with 0 out of 7 criteria passed.

Financials: revenue is $7M, +0%/yr average growth. Net income is $450.5B (loss), growing at -2434579.8%/yr. Net profit margin is -6881335% (negative). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $251M against $239M equity (Debt-to-Equity (D/E) ratio 1.05, moderate). Current ratio is 0.33 (tight liquidity). Debt-to-assets is 0.1%. Total assets: $306.3B.

Analyst outlook: 0 / 1 analysts rate ATNF as buy (0%) — mixed sentiment.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 15/100 (Fail), Past 0/100 (Fail), Health 17/100 (Fail), Moat 23/100 (Fail), Future 20/100 (Fail), Income 10/100 (Fail).

ATNF SharesGrow Score Overview

17/100

SharesGrow Score

Weak fundamentals

View full scorecard →

VALUE 0/100

Valuation — P/E, PEG, Forward PEG

GROWTH 15/100

Financials — average growth

PAST 0/100

strong — trend

HEALTH 17/100

Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is

MOAT 23/100

Gross margin is + market cap

FUTURE 20/100

Analyst outlook — as buy

INCOME 10/100

Net profit margin is

Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — ATNF

No analyst coverage available for this stock.

ATNF: +0%/yr revenue is, -2434579.8%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

View details →

No analyst coverage available for this stock.

Balance sheet ATNF: Debt-to-Equity (D/E) ratio 1.05 (moderate), Current ratio is 0.33 (tight liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

View details →

ATNF: Gross margin is 0% (+0 pp trend), $1B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 23/100. ≥ 70 = Pass.

View details →

Analyst outlook: 0 / 1 analysts rate ATNF as buy (0%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.

View details →

ATNF: Net profit margin is -6881335%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.

View details →

Stock Chart & Stats

Market Data

52-Week Range0.6578-17.75

Volume11.63M

Avg Volume (30D)9.83M

Market Cap$1.08B

Beta (1Y)0.41

Share Statistics

EPS (TTM)-5,517.71

Shares Outstanding$81.65M

IPO Date2017-06-27

Employees4

CEOLloyd Blair Jordan

Financial Highlights & Ratios

Revenue (TTM)$6.55M

EBITDA$-233.45B

Net Income$-450.52B

Operating Income$-233.45M

Total Cash$8.02B

Total Debt$251M

Net Debt$-7.77B

Total Assets$306.3B

Price / Earnings (P/E)-0

Price / Sales (P/S)164.56

Analyst Forecast

Rating ConsensusHold

Analysts Covering1

Buy 0% Hold 100% Sell 0%

Company Info

CountryUS

ExchangeNASDAQ Capital Marke

CurrencyUSD

ISINUS68236V3024

Price Chart

ATNF

ETHZilla Corporation Common Stock ↗ · NASDAQ Capital Marke

Healthcare • Biotechnology

0.66 52WK RANGE 17.75

People Also View

Immix Biopharma, Inc.

Zura Bio Limited

Palisade Bio, Inc.

Phio Pharmaceuticals Corp.

Sonnet BioTherapeutics Holdings, Inc.

Cardio Diagnostics Holdings, Inc.

ZyVersa Therapeutics, Inc.

Contact Us

🎓

SharesGrow Academy

Learn how to calculate Intrinsic Value and find undervalued stocks.

Weekly live sessions

📧 [email protected]

📞 +65 8912 8000

Send us a message